Cargando…

New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis

Lateral epicondylitis is a common source of elbow pain. Though it is often a self-limited condition, refractory lateral epicondylitis can lead to problems with activities of daily living and sometimes requires sick leave from work. Therefore prompt treatment is essential. Histopathologic studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahlenberg, Cynthia A., Knesek, Michael, Terry, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465648/
https://www.ncbi.nlm.nih.gov/pubmed/26114106
http://dx.doi.org/10.1155/2015/439309
_version_ 1782376108163858432
author Kahlenberg, Cynthia A.
Knesek, Michael
Terry, Michael A.
author_facet Kahlenberg, Cynthia A.
Knesek, Michael
Terry, Michael A.
author_sort Kahlenberg, Cynthia A.
collection PubMed
description Lateral epicondylitis is a common source of elbow pain. Though it is often a self-limited condition, refractory lateral epicondylitis can lead to problems with activities of daily living and sometimes requires sick leave from work. Therefore prompt treatment is essential. Histopathologic studies have suggested that lateral epicondylitis is a tendinopathy, associated with apoptosis and autophagy, rather than a tendonitis associated with inflammation. Although corticosteroids have been used for short-term treatment, recent studies have suggested that they are not helpful and may even be harmful and delay healing in the treatment of lateral epicondylitis. Researchers have recently begun to investigate the use of biologics as potential treatment options for lateral epicondylitis. Autologous blood preparations including platelet rich plasma (PRP) and autologous whole blood injections (ABIs) have been proposed in order to deliver growth factors and other nutrients to the diseased tendon. Stem cell therapies have also been suggested as a method of improving tendon healing. This review discusses the current evidence for the use of PRP, ABI, and stem cell therapies for treatment of lateral epicondylitis. We also review the evidence for nonbiologic treatments including corticosteroids, prolotherapy, botulinum toxin A, and nitric oxide.
format Online
Article
Text
id pubmed-4465648
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-44656482015-06-25 New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis Kahlenberg, Cynthia A. Knesek, Michael Terry, Michael A. Biomed Res Int Review Article Lateral epicondylitis is a common source of elbow pain. Though it is often a self-limited condition, refractory lateral epicondylitis can lead to problems with activities of daily living and sometimes requires sick leave from work. Therefore prompt treatment is essential. Histopathologic studies have suggested that lateral epicondylitis is a tendinopathy, associated with apoptosis and autophagy, rather than a tendonitis associated with inflammation. Although corticosteroids have been used for short-term treatment, recent studies have suggested that they are not helpful and may even be harmful and delay healing in the treatment of lateral epicondylitis. Researchers have recently begun to investigate the use of biologics as potential treatment options for lateral epicondylitis. Autologous blood preparations including platelet rich plasma (PRP) and autologous whole blood injections (ABIs) have been proposed in order to deliver growth factors and other nutrients to the diseased tendon. Stem cell therapies have also been suggested as a method of improving tendon healing. This review discusses the current evidence for the use of PRP, ABI, and stem cell therapies for treatment of lateral epicondylitis. We also review the evidence for nonbiologic treatments including corticosteroids, prolotherapy, botulinum toxin A, and nitric oxide. Hindawi Publishing Corporation 2015 2015-05-31 /pmc/articles/PMC4465648/ /pubmed/26114106 http://dx.doi.org/10.1155/2015/439309 Text en Copyright © 2015 Cynthia A. Kahlenberg et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kahlenberg, Cynthia A.
Knesek, Michael
Terry, Michael A.
New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis
title New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis
title_full New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis
title_fullStr New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis
title_full_unstemmed New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis
title_short New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis
title_sort new developments in the use of biologics and other modalities in the management of lateral epicondylitis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465648/
https://www.ncbi.nlm.nih.gov/pubmed/26114106
http://dx.doi.org/10.1155/2015/439309
work_keys_str_mv AT kahlenbergcynthiaa newdevelopmentsintheuseofbiologicsandothermodalitiesinthemanagementoflateralepicondylitis
AT knesekmichael newdevelopmentsintheuseofbiologicsandothermodalitiesinthemanagementoflateralepicondylitis
AT terrymichaela newdevelopmentsintheuseofbiologicsandothermodalitiesinthemanagementoflateralepicondylitis